Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

66.63 +58.90 (+761.97%)
Streaming Delayed Price Updated: 2:12 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,793,059
Open 21.07
Bid (Size) 66.50 (3)
Ask (Size) 67.00 (2)
Prev. Close 7.730
Today's Range 20.20 - 73.50
52wk Range 4.560 - 13.79
Shares Outstanding 34,422,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with... 
Via Benzinga

Performance

YTD
+559.7%
+559.7%
1 Month
+779.2%
+779.2%
3 Month
+779.0%
+779.0%
6 Month
+811.5%
+811.5%
1 Year
+665.9%
+665.9%

More News

Read More
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
Via Benzinga
Topics Stocks
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy
Via Stocktwits
A Look at MiNK Therapeutics's Upcoming Earnings Report
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
Via Benzinga
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Via Chartmill
These stocks are moving in today's session
Via Chartmill
The market is filled with gapping stocks in Tuesday's session.
Via Chartmill
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
What is the current price of MiNK Therapeutics, Inc. - Common Stock?
The current price of MiNK Therapeutics, Inc. - Common Stock is 66.63
When was MiNK Therapeutics, Inc. - Common Stock last traded?
The last trade of MiNK Therapeutics, Inc. - Common Stock was at 07/11/25 02:12 PM ET
What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 2.29B
How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
MiNK Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.